Compare · BCRX vs XFOR
BCRX vs XFOR
Side-by-side comparison of BioCryst Pharmaceuticals Inc. (BCRX) and X4 Pharmaceuticals Inc. (XFOR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCRX and XFOR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BCRX is the larger of the two at $2.52B, about 6.6x XFOR ($382.0M).
- Over the past year, BCRX is up 9.9% and XFOR is up 183.0% - XFOR leads by 173.1 points.
- XFOR has been more active in the news (7 items in the past 4 weeks vs 4 for BCRX).
- BCRX has more recent analyst coverage (25 ratings vs 9 for XFOR).
- Company
- BioCryst Pharmaceuticals Inc.
- X4 Pharmaceuticals Inc.
- Price
- $9.86-0.55%
- $4.16+2.59%
- Market cap
- $2.52B
- $382.0M
- 1M return
- +16.08%
- +7.63%
- 1Y return
- +9.87%
- +182.99%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1994
- 2017
- News (4w)
- 4
- 7
- Recent ratings
- 25
- 9
BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase I clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. BioCryst Pharmaceuticals, Inc. has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. The company was founded in 1986 and is headquartered in Durham, North Carolina.
X4 Pharmaceuticals Inc.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rear diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest BCRX
- Analyst resumed coverage on BioCryst Pharma with a new price target
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst Pharmaceuticals Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits
- BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility
- Director Milne Jill C. was granted 15,294 shares, increasing direct ownership by 92% to 31,938 units (SEC Form 4)
- Director Galson Steven K was granted 15,294 shares, increasing direct ownership by 122% to 27,794 units (SEC Form 4)
- Director Levin Alan G was granted 15,294 shares, increasing direct ownership by 24% to 79,565 units (SEC Form 4)
- Director Frank Steven was granted 15,294 shares, increasing direct ownership by 76% to 35,459 units (SEC Form 4)
- Director Sanders Machelle was granted 15,294 shares, increasing direct ownership by 50% to 45,936 units (SEC Form 4)
- Director Milano Vincent was granted 15,294 shares, increasing direct ownership by 16% to 108,483 units (SEC Form 4)
Latest XFOR
- Wells Fargo initiated coverage on X4 Pharmaceuticals with a new price target
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Financial Officer Kirske David sold $36,428 worth of shares (8,543 units at $4.26), decreasing direct ownership by 5% to 167,750 units (SEC Form 4)
- SEC Form 4 filed by Director Gold Kelly
- SEC Form 3 filed by new insider Gold Kelly
- X4 Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors
- Leerink Partners initiated coverage on X4 Pharmaceuticals with a new price target
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference